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Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute
Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been
associated with increased mortality in ACS patients with an increase in number of Stent
Thrombosis. This review article tries to find out the causes of Clopidogrel Resistance, the
main factors involving it, Laboratory evaluation of Clopidogrel Resistance. The overall
incidence of Clopidogrel Resistance across the Globe & India has also been considered. The
article also discusses the clinical significance of Clopidogrel Resistance & its relationship
with adverse cardiovascular events. This review ends with the probable solutions to Clo-
pidogrel Resistance & the new generation of antiplatelets which can be used for the same.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Clopidogrel inhibits platelet activation and inhibition by
selectively and irreversibly blocking P2Y12 receptor.1 The
CAPRIE (Clopidogrel versus Aspirin in Patients at risk of
Ischemic Events) study demonstrated the benefit of using
clopidogrel þ Aspirin compared to Aspirin alone in selected
patients due to the different receptor and pathway of inhibi-
tion.2 Combined therapy of Clopidogrel with Aspirin is
considered in all patients with acute coronary syndromes
requiring Percutaneous Intervention (PCI).3 The benefit of
combined therapy in major trials was also associated with
adverse ischemic events including stent thrombosis. The
previous trials were focused on the clinical events without the
laboratory evaluation of platelet function. Laboratory assess-
ment of non-responsiveness to clopidogrel was shown to be
associated with adverse ischemic events..
ciety of India. All rights2. Mechanism of action
Clopidogrel acts by inhibiting ADP induced platelet aggrega-
tion. It also inhibits collagen and thrombin induced platelet
aggregation which can be overcome by increased concentra-
tion of these agonists. Clopidogrel is rapidly absorbed from the
intestine and converted to a short lived active metabolite by
hepatic cytochrome P450 enzymes (CYP3A4, CYP3A5, and
CYP2C19). The active metabolite permanently binds to the
P2Y12 receptor via disulphide bridges and there is inhibition
of platelet activation.43. Clopidogrel resistance
Clopidogrel Resistance is defined as the failure of themolecule
to inhibit the target of its action. Clopidogrel resistance is bestreserved.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 3 0e5 3 4 531demonstrated by the evidence of residual post treatment
P2Y12 activity bymeasuring ADP induced platelet aggregation
before and after treatment. No single receptor signaling
pathway mediated platelet activation is responsible for its
activity. Therefore a single treatment strategy may not be
sufficient to overcome clopidogrel resistance.54. Laboratory evaluation of clopidogrel
responsiveness
A standardizedmethod to evaluate in-vivo platelet response is
still lacking. Clopidogrel inhibits one of the two ADP receptors;
ex-vivo measurement of ADP induced platelet aggregation
by light transmittance aggregometry is the most commonly
used “Gold standard” method to evaluate clopidogrel
responsiveness.6
Lately it was suggested that since clopidogrel induced
platelet disaggregation was better demonstrated by
measuring late platelet aggregation at 6 min after stimulation
with ADP rather thanmaximum aggregation. Flow cytometric
measurements of expression of GpIIb/IIIa receptor and p
selectin expression after ADP stimulation can also identify
clopidogrel nonresponsiveness. In addition, measurements of
ADP induced fibrin clot strength is measured by whole blood
throomboelastography and the verify Now P2Y12 receptor
assay using ADP as agonist. The PFA-100 method using
collagen ADP based cartridges and whole blood aggregometry
are associated with inconsistent estimates of platelet reac-
tivity to ADP. The phosphorylation state of vasodilator stim-
ulated phosphoprotein is a specific intracellular marker for
residual P2Y12 receptor reactivity in patients treated with
clopidogrel, but the method is difficult.75. Clopidogrel resistance & time of treatment
The prevalence of clopidogrel resistance in various studies
was 5%e44%.4 Refer to Table 1.
Increasing the loading dose of clopidogrel to 600 mg is
helpful in reducing resistance. Response variability to treat-
ment with clopidogrel was seen in patients who were on
clopidogrel post PCI. If the pre and post treatment ADP
induced platelet aggregation was <10%, these patients wereTable 1 e Clopidogrel resistance world wide data.
Investigators Number of pati
Jaremo et al (J Invest Med.2002;252:233) 18
Gurbel et al (Circulation 2003;107:2908) 92
Muller et al (Thromb Haemost 2003;89:783) 105
Mobley et al (Am J Cardiol 2004;93:456) 50
Lepantalo et al (Eur Heart J 2004;25e476) 50
Angiolillo et al (Thromb Res 2005;115:101) 48
Matetzky et al (Circulation 2004;109:3171) 60
Dzieweierz (Kardiol Pol 2005;62:108) 31
Gurbel et al (J Am Coll Cardiol 2005;45:1392) 192
Lev et al (J Am Coll Cardiol 2006;47:27) 150
Data adapted from: Gurbel PA, Tantry US. Clopidogrel Resistance? Thromdefined as “Clopidogrel Resistant”.8 A subgroup of patients
hadmore platelet aggregation post Percutaneous Intervention
(PCI) than before they were defined as “Heightened Platelet
Reactivity to ADP”.96. Relation of clopidogrel resistance to
adverse clinical events
The data linking clopidogrel resistance to clinical events are
limited. Matetzky et al studied clopidogrel responsiveness in
patients undergoing Stenting for ST elevated MI and found
that patients who exhibited the highest quartile of ADP
induced aggregation had a 40% probability of recurrent car-
diovascular event in 6 months. Their study concluded that
upto 25% STEMI (ST elevated Myocardial Infarction) patients
would suffer from Stent Thrombosis due to clopidogrel
Resistance.10
In PREPARE POST STENTING study (Platelet Reactivity in
Patients and Recurrent Events POST STENTING), patients
suffering from recurrent ischemic events within 6 months of
Stenting had a high platelet reactivity to ADP than those
without ischemic complications.9
In the CLEAR PLATELETS (Clopidogrel Loading with Eptifi-
batide to Arrest PLATELET reactivity) and CLEAR PLATELETS
1b studies, a 600 mg clopidogrel loading dose used to treat
patients undergoing elective Stenting was associated with
superior early platelet inhibition compared to a loading dose
of 300 mg and this inhibition was associated with decrease in
myocardial necrosis and inflammatory markers.11
These findings suggest that high platelet reactivity despite
currently recommended antiplatelet therapy is a risk factor
for ischemia in patients undergoing PCI.7. Clopidogrel resistance in India
There is limited number of studies conducted on clopidogrel
resistance in India. The results of these studies indicate that
prevalence of clopidogrel resistance in India is in line with
global scenario.
In a trialwith 144ACS (AcuteCoronary Syndromes) Patients
in Kolkata by Guha et al clopidogrel resistance was seen in
12.5% of patients and 19.44% patients were poor responders.12ents Clopidogrel loading dose Resistance
300 28%
300 31e35%
600 5e11%
300 30%
300 40%
300 44%
300 25%
300 23%
300/600 8e32%
300 24%
5e44%
b Res. 2007; 120(3):311e21. Epub 2006 Nov 14.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 5 3 0e5 3 4532Another study conducted by Kumar, Saran et al in 39 ACS
patients showed 2.54% patients as clopidogrel resistant &
12.70% patients were termed as clopidogrel Semi resistant.13
A study conducted by Kar, Meena et al in 100 CAD Patients
showed 19% patients as semi resistant& 13%were found to be
poor responders.148. Mechanisms of clopidogrel resistance
Differences in intestinal absorption, hepatic conversion of
activemetabolite through cytochrome CYP2C19, ABC1 activity
and platelet receptor polymorphisms have been suggested.
Higher loading dose of clopidogrel 600mgwas associatedwith
increased inhibition of ex-vivo ADP induced platelet aggrega-
tion in patients undergoing PCI and decreased prevalence of
non-responders.CYP-450 (particularly CYP2C19, CYP3A4 and
CYP3A5) enzymes play a vital role in generating the active
metabolite of clopidogrel hence variation in production of
thoseenzymesmaybe responsible for clopidogrel resistance.15
Genetic polymorphism of ABC1 as well as GpIIb-IIIa, GPIa-
IIa and P2Y12 receptors also causes clopidogrel resistance.
Patients with Diabetes exhibit heightened platelet reactivity
and this may further aggravate non responsiveness to
clopidogrel.5
Insufficientmetabolite generation secondary to limitations
in intestinal absorption, Drug-drug interaction at CYP 3A4 or
genetic polymorphism of CYP isoenzymes are seen as the
primary explanations for resistance rather than genetic
polymorphism of platelet receptors or intracellular signaling
mechanisms. It may be relevant in those patients who remain
resistant and with high platelet reactivity to ADP even after
high dosing strategies.9. Management of clopidogrel resistance
9.1. Higher doses of clopidogrel
Asmentioned earlier, various studies have shown that 600mg
dose was associated with higher level of platelet inhibition,
lower mean post treatment reactivity of ADP than the 300 mg
loading dose.
The CURRENT OASIS-7 (Double-dose versus standard-dose
clopidogrel and high dose versus low-dose aspirin in in-
dividuals undergoing percutaneous coronary intervention for
acute coronary syndromes) trial randomized 25,087 patients
with unstable angina or acute MI to a high dose regimen
(600 mg loading dose of clopidogrel, followed by 150 mg per
day for 1 week) or the standard regimen (300 mg on the first
day followed by 75 mg/day) showed benefit of 600 mg clopi-
dogrel in ACS þ PCI population but the primary end point was
mainly driven by MI alone. The Current OASIS trial however
showed a significant reduction in Definite Stent Thrombosis
(58 [0.7%] vs. 111 [1.3%]; 0.54 [0.39e0.74], p ¼ 0.0001).16
GRAVITAS (Gauging Responsiveness with A Verify Now
assaydImpact on Thrombosis And Safety) trial, the first large-
scale clinical trial, designed to examine whether adjustment
of clopidogrel therapy, on the basis of platelet function testing
using a point-of-care assay, safely improves outcome after PCIwith drug-eluting stents in clopidogrel resistant patients, did
not show any superiority of 150 mg vs. 75 mg of clopidogrel.17
In the CLEAR PLATELETS (Clopidogrel Loading with Eptifi-
batide to Arrest the Reactivity of Platelets) study; 600 mg
loading dose was associated with a superior pharmacody-
namic antiplatelet profile compared to a 300 mg clopidogrel
loading dose, in the absence of a GPIIb/IIIa (Glycoprotein IIb/
IIIa) inhibitor.11
However, in the recent ISARCHOICE (Intracoronary Stent-
ing and Antithrombotic Regimen: Choice Between 3 High Oral
doses for Immediate Clopidogrel Effect) Study, there was a
ceiling effect in unchanged clopidogrel and clopidogrel
metabolite levels and platelet inhibition with the 600 mg
loading dose, and no significant additional effect was seen
with the 900 mg loading dose.18
Recently ACC/AHA Guidelines recommended a Class IIb
recommendation that “In patients in whom sub acute
thrombosis may be catastrophic or lethal, platelet aggregation
studies may be considered and the dose of clopidogrel needs
to be increased to 150 mg per day if less than 50% inhibition of
platelet aggregation is demonstrated.”1910. New P2Y12 receptor antagonists:
Prasugrel
Prasugrel is a novel thienopyridine introduced for the treat-
ment of acute coronary syndromes.
Jernberg & Wallentine et al published that Prasugrel
demonstrated higher and more rapid inhibition of platelet
aggregationandagreater reductionofpharmacodynamicnon-
responders, compared with the standard clopidogrel dose of
75 mg.20
In another study Alexopoulos et al demonstrated in their
trial that in ACS patients who are on HTPR (high on treatment
platelet reactivity) after PCI (Percutaneous Intervention) Prasu-
grel is more effective compared to high dose clopidogrel in
reducingplatelet reactivity, particularly inCYP2C19*2carriers.21
In recent ACAPULCO (Prasugrel Compared with High Dose
Clopidogrel in ACS) study by Montalescot et al reinforced this
observation by proving prasugrel's superiority in platelet in-
hibition compared to high dose clopidogrel MD 150 mg or
900 mg LD.2211. Newer P2Y12 receptor antagonists:
Ticagrelor & cangrelor
Ticagrelor an oral, direct-acting, reversible, P2Y12 receptor
antagonist, was associated with less ischemic event occur-
rence than clopidogrel in patients with acute coronary syn-
dromes in the Platelet Inhibition and Patient Outcomes
(PLATO) trial.23
In RESPOND study the response to ticagrelor in clopi-
dogrel non-responders in stable CAD patients was studied in
detail.24 In ticagrelor treated patients, platelet reactivity was
below the cut-off points previously associated with ischemic
riskdmeasured by LTA (Light Transmittance Aggregometry),
Verify Now P2Y12 assay, and VASP-P (Vasodilator Stimu-
lated Phosphoprotein phosphorylation)din 98%e100% of
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 3 0e5 3 4 533patients versus 44%e76% of patients after clopidogrel
Therapy (Figure below).
The study also demonstrated that ticagrelor therapy was
associated with greater platelet inhibition compared with
clopidogrel treatment in both clopidogrel responders and no
responders. It was found that the antiplatelet effect of tica-
grelor was not influenced by clopidogrel response status. It
was clearly evident that ticagrelor overcame clopidogrel
resistance. Nearly all patients during ticagrelor therapy, irre-
spective of clopidogrel response status, had platelet reactivity
below the cut-offs associated with ischemic risk determined
by all assays.
Switching from clopidogrel to ticagrelor not only overcame
clopidogrel nonresponsiveness (mean increase in IPA of
around 40% in non-responders) but also provided additional
platelet inhibition in clopidogrel responders (around 20% in-
crease in IPA).
Cangrelor, another reversible non-thienopyridine ADP re-
ceptor P2Y12 inhibitor, administered intravenously, was
assessed in the CHAMPION-PLATFORM74 and the CHAMPION-
PCI trials. Efficacy of Cangrelor in clopidogrel resistant pa-
tients is yet to be proved.2512. Conclusion
Clopidogrel was a gold standard drug and has been used in
combination with aspirin in patients with acute coronary
syndrome. In recent studies it has been shown that high on
platelet reactivity due to clopidogrel resistancewas associated
with adverse thrombotic events including stent thrombosis.
The primary reason is suboptimal generation of the active
metabolite due to individual variability in intestinal absorp-
tion, drug-drug interaction and polymorphism in the CYP
isoenzymes. Clopidogrel resistance has been documented in
the range of 5e44% across the world including India. Methods
to identify clopidogrel resistance are not standardized and not
freely available in India. One needs to confirm clopidogrel
resistance especially in high risk ACS patients (e.g. Diabetic
patients, Renal Compromised patients, Patients with prior h/o
Stroke, TIA etc). Use of higher loading doses of clopidogrel
(600 mg) or more potent P2Y12 receptor agents (e.g. prasugrel,ticagrelor, cangrelor) are the strategies to overcome clopi-
dogrel resistance.Conflicts of interest
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